Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1383&sort=-other_investigators
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-other_investigators", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=-other_investigators", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1384&sort=-other_investigators", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1382&sort=-other_investigators" }, "data": [ { "type": "Grant", "id": "10370", "attributes": { "award_id": "1K99HL164960-01", "title": "Endothelial cell signaling in regeneration of the lung", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 26342, "first_name": "MARISOL", "last_name": "Espinoza-Pintucci", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2024-08-31", "award_amount": 161690, "principal_investigator": { "id": 26343, "first_name": "Terren Kathryn", "last_name": "Niethamer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 232, "ror": "https://ror.org/00b30xv10", "name": "University of Pennsylvania", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "A critical function of the lung at homeostasis is delivery of oxygen to the blood through a process called gas exchange. When the lung is functioning normally, type I alveolar epithelial cells and capillary endothelial cells (ECs) lining blood vessels in the distal lung form a tight interface to exchange oxygen and carbon dioxide between them. However, when the lung is damaged by chronic disease, cancer, or infections such as influenza or COVID-19, this process can be hindered or even prevented. After lung injury, progenitor cells can regenerate the cell types required for gas exchange, but cell-cell communication is also essential to form a functional structure that restores delivery of oxygen to the blood. Development of improved regenerative therapies in the lung will therefore require a detailed knowledge of not only the specific cell types that are present, but also how they communicate to drive cell self-organization and morphogenesis. We have shown that capillary ECs in the distal lung are heterogeneous; one population acts as an EC progenitor and proliferates after acute injury (CAP2s), while a second population does not proliferate significantly after injury and possesses a larger, more complex morphology and high expression of signaling molecules (CAP1s). These EC subtypes clearly contribute differently to regeneration, but how distinct EC fates are established and maintained, the mechanisms that promote the preferential proliferation of CAP2s, and the signaling function of CAP1s remain unknown. In addition, the EC signaling mechanisms within the alveolar niche that are required to effect morphogenesis and rebuild the gas exchange interface remain incompletely understood. The proposed research will further develop my skills in transcriptomic and epigenomic analysis to address these questions and will integrate these skills with my previous training in mouse genetics, signaling, and cell behavior to establish a strong foundation on which to build an independent research career. My research program will focus on the role of EC signaling and behavior in regeneration of functional alveolar structures in the lung after acute injury. My primary mentor is Dr. Edward Morrisey, an internationally renowned scientist in the study of lung regeneration who has defined many key regulators of cell fate and signaling mechanisms in the lung. I have also assembled an advisory committee of experts in vascular biology, mouse and human organoid culture, epigenetics, and bioinformatics who will assist me with additional training in these areas. The proposed work will be conducted at the University of Pennsylvania, where I will benefit from the rich intellectual environment, extensive resources, collaborative scientific community in pulmonary and vascular biology, and the full support of the institution. Together, my proposed research and career development plans will facilitate a better understanding of the role of EC signaling in lung regeneration and aid in establishing my career as an independent investigator in pulmonary vascular biology.", "keywords": [ "ATAC-seq", "Acute", "Acute Lung Injury", "Address", "Advisory Committees", "Alveolar", "Alveolar Cell", "Alveolus", "Architecture", "Area", "Bioinformatics", "Biology", "Blood", "Blood Vessels", "Blood capillaries", "COVID-19", "Candidate Disease Gene", "Capillary Endothelial Cell", "Carbon Dioxide", "Cardiovascular system", "Cell Communication", "Cell Differentiation process", "Cell Line", "Cell Proliferation", "Cells", "Cellular biology", "Chronic Disease", "Communication", "Communities", "Complex", "Data", "Development", "Development Plans", "Distal", "Elastases", "Endothelial Cells", "Endothelium", "Environment", "Epigenetic Process", "Epithelial", "Epithelial Cells", "Foundations", "Functional Regeneration", "Gases", "Genetic Transcription", "Heterogeneity", "Homeostasis", "Human", "Image", "Immune", "Individual", "Infection", "Influenza", "Injury", "Institution", "International", "KDR gene", "Knock-out", "Knowledge", "Ligands", "Lung", "Lung diseases", "Malignant Neoplasms", "Mammals", "Mentors", "Mesenchymal", "Morphogenesis", "Morphology", "Mus", "Natural regeneration", "Organ", "Organoids", "Oxygen", "Patients", "Pennsylvania", "Phase", "Population", "Positioning Attribute", "Process", "Proliferating", "Pulmonary alveolar structure", "Pulmonary function tests", "Receptor Signaling", "Regenerative capacity", "Research", "Research Personnel", "Resources", "Role", "Scientist", "Signal Pathway", "Signal Transduction", "Signaling Molecule", "Site", "Structure", "Structure of parenchyma of lung", "Time", "Tissues", "Training", "Universities", "Vascular regeneration", "Viral", "Work", "alveolar epithelium", "career", "career development", "cell behavior", "cell regeneration", "cell type", "endothelial stem cell", "epigenomics", "genetic approach", "improved", "in vivo", "influenza infection", "injured", "injury and repair", "insight", "lung injury", "lung regeneration", "mouse genetics", "novel", "post-doctoral training", "prevent", "progenitor", "programs", "pulmonary function", "pulmonary vascular cells", "receptor", "reconstruction", "regenerative", "regenerative therapy", "repaired", "research and development", "response", "self organization", "severe injury", "single-cell RNA sequencing", "skills", "stem cells", "transcriptome sequencing", "transcriptomics" ], "approved": true } }, { "type": "Grant", "id": "10371", "attributes": { "award_id": "1U01FD007769-01", "title": "DDT-BMQ-000079 Establishing Performance Characteristics of the Epidermal Neurite Density (END) Biomarker to Assist Diagnosis of Small Fiber Neuropathy", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 26344, "first_name": "York", "last_name": "Tomita", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2023-08-31", "award_amount": 248415, "principal_investigator": { "id": 26345, "first_name": "Anne Louise LOUISE", "last_name": "Oaklander", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 736, "ror": "https://ror.org/002pd6e78", "name": "Massachusetts General Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "In the polyneuropathies, adverse conditions damage the body’s peripheral neurons, causing them to fire dysfunctionally and sometimes begin to degenerate. Small-fiber neuropathy (SFN) is a very common type. Many neuropathies, including from diabetes or toxic exposures, often affect the ends of smaller fibers earliest or most severely. Sensory, chronic tingling, itch, and numbness, typically starting in the feet and lower legs then spreading upwards are external symptoms of SFN. However, as most of the autonomic axons that innervate and regulate the body systems are also small-diameter fibers, SFN also causes internal symptoms–intolerance of usual level of exertion, profound fatigue, lightheadedness, rapid heart rate, and gastrointestinal symptoms. SFN is not detected by the standard diagnostic biomarker for large-fiber neuropathies (electromyography and nerve conduction study). Instead, END (epidermal neurite density) measurements are made from tiny punch biopsies from the lower leg. Along with clinical indicators, this biomarker is validated to identify suspected cases. Skin biopsy testing is integral to the first formal case definition of SFN from uncertain cause, formulated by a global expert ACTTION Committee meeting supported by FDA, NIH, and industry. This group, that included the P.I., recommended END measurement as mandatory for clinical trial inclusion (Freeman, R. et al. Neurology, 2020). Hence this request for biomarker qualification for a diagnostic test increasingly used including for clinical and treatment research, despite sometimes varying methodological details and analyses between accredited university and commercial U.S. labs. Any inconsistencies increase risk that the same biopsy could generate different END numbers and/or divergent interpretations. Clinical research studies using END measurements for inclusion or outcomes might enroll slightly different participants or generate different efficacy data that could influence FDA approval. In 2022, Dr. Oaklander and others linked SFN to long-COVID illnesses, so long-COVID studies including NIH’s RECOVER are considering adding END measurement. The objective of the proposed studies is to identify and then validate best methods of obtaining and analyzing the END biomarker. The Aims respond to the applicants’ DDTBMQ000079 LOI approval to generate a full Biomarker Qualifier Plan. Aim I analyzes anonymized END measurements and other data from a large US diagnostic skin biopsy lab dataset of healthy controls and patients to identify knowledge gaps, then compare and validate potential solutions. Aim II adds prospective biopsies where needed. Aim III includes other stakeholders including outside accredited labs for cross-validation and neurological societies to generate Guidelines. Standard operating procedures would be improved throughout, and statistical modeling for END distribution, including selection of variables and algorithms, would be optimized and validated.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10372", "attributes": { "award_id": "1R56HL160545-01A1", "title": "Restoring immune-vascular axis integrity to alleviate acute lung injury in sepsis", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 22454, "first_name": "GUOFEI", "last_name": "Zhou", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2023-08-31", "award_amount": 391250, "principal_investigator": { "id": 26346, "first_name": "Krishnendu", "last_name": "Pal", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1414, "ror": "", "name": "MAYO CLINIC JACKSONVILLE", "address": "", "city": "", "state": "FL", "zip": "", "country": "United States", "approved": true }, "abstract": "Sepsis-induced multi organ dysfunction syndrome, which primarily affects the lungs and kidneys, is a major cause of morbidity and mortality worldwide. Acute lung injury (ALI) or its most severe form, acute respiratory distress syndrome (ARDS), are the most common complications of sepsis, for which no effective treatment except supportive care is available. Hence, novel therapeutic strategies for mitigating sepsis-induced ALI are desperately needed, more so in the face of the current SARS-CoV-2 pandemic. Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to an infection, where both immune cells and endothelial cells play critical roles. Pathogen-induced inflammatory cascade and the endothelium impact each other via autocrine or paracrine loops to increase vascular permeability and cause immune dysregulation to disrupt immune-vascular homeostasis. Hence, therapies aimed towards reinstating immune-vascular homeostasis are needed to alleviate sepsis-induced complications like ALI/ARDS. Neuropilin-1 (NRP1), implicated in vascular permeability and inflammation, may prove to be a viable target for treating sepsis-induced ALI by restoring immune-vascular integrity. Hence, the central hypothesis of our proposal is that NRP1 plays a critical role in the immune-vascular dysfunction in sepsis-induced ALI and targeting NRP1 for restoring the immune-vascular homeostasis is a viable therapeutic option for this disease. To validate our hypothesis, we propose three specific aims. In Aim 1, we will analyze the effect of ALI- relevant cytokines in vitro in mouse lung endothelial cells isolated from endothelial-specific NRP1 knockout mice. We will also develop ALI in these mice by high dose lipopolysaccharides (LPS) treatment or by cecal ligation and puncture (CLP) to evaluate the role of endothelial NRP1 in the severity of sepsis-induced ALI, in vivo vascular permeability, leukocyte rolling and extravasation. Aim 2 will investigate the effect of coculturing peripheral blood mononuclear cells (PBMCs) isolated from myeloid-specific and CD4+T-cell specific NRP1- knockout mice with wild-type mouse lung endothelial cells. Moreover, we will develop ALI in these NRP1- knockout mice models to investigate the pleotropic role of NRP1 in these two immune cell populations during sepsis-induced ALI. Aim 3 will evaluate the therapeutic efficacy of an endothelial cell (EC)-targeting liposomal formulation of a small-molecule NRP1 inhibitor (EG00229), in ameliorating the severity of sepsis-induced ALI. We anticipate that our proposal will provide a deeper insight into the role of NRP1 in the immune- vascular dysfunction in sepsis-induced ALI and lead to the development of a viable therapeutic strategy of targeting NRP1 to overcome its severity. The ultimate goal of our proposal is to benefit a large number of patients suffering from sepsis-induced lung complications for which there is no effective therapy till date.", "keywords": [ "Accounting", "Acute Lung Injury", "Acute Respiratory Distress Syndrome", "Affect", "Blood Vessels", "CD4 Positive T Lymphocytes", "COVID-19 pandemic", "Cells", "Cessation of life", "Clinical", "Coculture Techniques", "Complication", "Development", "Disease", "Dose", "Endothelial Cells", "Endothelium", "Extravasation", "Formulation", "Functional disorder", "Future", "Goals", "Homeostasis", "Immune", "Immune response", "In Vitro", "Infection", "Inflammatory", "Intensive Care Units", "Kidney", "Knock-out", "Knockout Mice", "Lead", "Leukocyte Rolling", "Life", "Ligands", "Lipopolysaccharides", "Liposomes", "Lung", "Monitor", "Morbidity - disease rate", "Multiple Organ Failure", "Mus", "Myelogenous", "NRP1 gene", "Neuropilin-1", "Organ", "Pathogenesis", "Pathologic Processes", "Pathology", "Patient-Focused Outcomes", "Patients", "Peripheral Blood Mononuclear Cell", "Permeability", "Platelet-Derived Growth Factor", "Play", "Population", "Process", "Role", "Sepsis", "Severities", "Signal Transduction", "Supportive care", "Syndrome", "Therapeutic", "Tidal Volume", "Tissues", "Transforming Growth Factors", "Treatment Efficacy", "Tumor-infiltrating immune cells", "Vascular Diseases", "Vascular Endothelial Growth Factors", "Vascular Permeabilities", "Wild Type Mouse", "autocrine", "cecal ligation puncture", "clinical application", "cytokine", "cytokine release syndrome", "effective therapy", "efficacy evaluation", "in vivo", "inhibitor", "insight", "mortality", "mouse model", "novel therapeutic intervention", "paracrine", "pathogen", "receptor", "response", "sepsis induced acute lung injury", "septic patients", "small molecule", "systemic inflammatory response", "targeted delivery", "therapeutic evaluation", "therapeutically effective", "two photon microscopy", "vascular inflammation" ], "approved": true } }, { "type": "Grant", "id": "10375", "attributes": { "award_id": "1R15DA055201-01A1", "title": "Neurobiological characterization of sex differences in somatic, motivational, and emotional aspects of opiate withdrawal", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 26351, "first_name": "SUNILA GOPI", "last_name": "Nair", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2023-08-31", "award_amount": 453892, "principal_investigator": { "id": 26352, "first_name": "Linda Irene", "last_name": "Perrotti", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1843, "ror": "", "name": "UNIVERSITY OF TEXAS ARLINGTON", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "Opioid use disorder (OUD) has reached epidemic proportions, with over 1,000 daily emergency room visits, and claiming ~130 lives per day, to opioid overdoses in the U.S. The Covid-19 pandemic has only made matters worse. Opioids significantly affect men and women differently, yet most of what is known about opioid dependence and withdrawal has been derived from studies exclusively in men and then extrapolated to women; and parameters used to delineate the neurobiology of opioid withdrawal (OW) syndrome have been developed using male subjects. This represents significant gaps in our understanding; filling such gaps will help devise better, sex- based, treatment strategies. Our long-term objective is to understand basic behavioral and neural processes underlying OW that will inform the development of strategies to improve treatment outcomes that someday could facilitate the matching of patients to treatments. To this end, the research Aims outlined in this application will begin to fill three important gaps in our knowledge. First Gap: Studies of OUD show that women suffer from more severe emotional and physical withdrawal as compared to men, yet the few basic studies assessing sex differences in OW show inconsistent results. We will characterize sex differences in the onset, expression, and duration of somatic, motivational, and emotional symptoms of acute and protracted OW syndrome in male and female rats over the course of the estrous cycle. We hypothesize that severity and persistence of OW symptoms vary as a function of gonadal hormone status in males and females. Second Gap: Severity and mismanagement of OW symptoms are primary contributors to attrition from treatment. Women are at an increased risk for dropping out; and available treatments have unwanted effects, especially when prescribed, or combined, with benzodiazepines, a therapeutic highly prescribed to, and utilized by, women. Thus, new medication approaches are much needed. We will begin to fill this gap by assessing the efficacy of ketamine (KET) in alleviating OW symptomatology. We hypothesize that KET will be efficacious in ameliorating OW symptomatology. Third Gap: Knowledge of the neural mechanism(s) underlying OW has been derived from studies in males, showing that cAMP-activated-CREB is essential for alterations in gene expression that precipitate OW. The effects of OW on cAMP-PKA-CREB activity in the tail of the ventral tegmental area/rostromedial tegmental nucleus (tVTA/RMTg), a brain region we first described to respond to chronic drug exposure and aversive stimuli, are just beginning, and only one study from our lab has been performed in females. We will begin establishing causal relationships by examining the functional significance of CREB expression in the tVTA/RMTg during OW, selectively regulating CREB activity in tVTA/RMTg neurons to assess the severity and persistence of OW symptoms in male and female rats using viral vector gene-transfer technology. The research proposed here will begin to provide a greater understanding of the systemic effects and fundamental pathways underlying sex differences in OW.", "keywords": [ "Abstinence", "Acute", "Address", "Adverse effects", "Affect", "Analgesics", "Antidepressive Agents", "Anxiety", "Area", "Attenuated", "Aversive Stimulus", "Behavior", "Behavior assessment", "Behavioral", "Benzodiazepines", "Brain region", "COVID-19 pandemic", "CREB1 gene", "Cell Nucleus", "Chronic", "Clinical Research", "Cyclic AMP", "Cyclic AMP-Dependent Protein Kinases", "Data", "Development", "Distress", "Drops", "Drug Exposure", "Emergency department visit", "Emotional", "Environment", "Epidemic", "Estrous Cycle", "Female", "Funding", "Future", "Gene Expression", "Gonadal Hormones", "Grant", "Health", "Human", "Institution", "Ketamine", "Knowledge", "Mediating", "Mental Depression", "Minority-Serving Institution", "Molecular", "Moods", "Motivation", "NMDA receptor antagonist", "Nature", "Neurobiology", "Neurons", "Neurosciences", "Operative Surgical Procedures", "Opiate Addiction", "Opioid", "Opioid agonist", "Pain", "Pain management", "Pathway interactions", "Patients", "Pharmaceutical Preparations", "Pharmacotherapy", "Process", "Property", "Rattus", "Regulation", "Reporting", "Research", "Research Training", "Risk", "Rodent", "Role", "Science", "Severities", "Sex Differences", "Signal Transduction", "Simplexvirus", "Students", "Substance Withdrawal Syndrome", "Substance abuse problem", "Symptoms", "Tail", "Technology Transfer", "Testing", "Therapeutic", "Time", "Treatment Efficacy", "Treatment outcome", "Underrepresented Populations", "United States National Institutes of Health", "Ventral Tegmental Area", "Viral", "Viral Vector", "Withdrawal", "Withdrawal Symptom", "Woman", "Work", "acute symptom", "base", "career", "comorbidity", "emotional symptom", "experience", "experimental study", "gene transfer vector", "gonad function", "improved", "male", "men", "mu opioid receptors", "negative affect", "neuromechanism", "novel therapeutics", "opiate tolerance", "opioid agonist therapy", "opioid overdose", "opioid use", "opioid use disorder", "opioid withdrawal", "overexpression", "pre-clinical research", "relating to nervous system", "sex", "symptomatology", "training opportunity", "translational potential", "treatment program", "treatment strategy" ], "approved": true } }, { "type": "Grant", "id": "10376", "attributes": { "award_id": "1RF1MH132337-01", "title": "Leveraging genomic data to dissect the association of internalizing disorders with the risk, onset, and vulnerability of COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Mental Health (NIMH)" ], "program_reference_codes": [], "program_officials": [ { "id": 26353, "first_name": "Tara", "last_name": "Dutka", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2025-08-31", "award_amount": 3694722, "principal_investigator": { "id": 26354, "first_name": "RENATO", "last_name": "POLIMANTI", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 452, "ror": "https://ror.org/03v76x132", "name": "Yale University", "address": "", "city": "", "state": "CT", "zip": "", "country": "United States", "approved": true }, "abstract": "Abstract. Although our understanding of the COVID-19 and its infectious agent, SARS-Cov-2, is greatly improved and effective vaccines have been developed, there are many uncertainties regarding how and when the pandemic is going to end. Additionally, there are many consequences due to the pervasive impact of COVID-19 on individuals and societies that we will continue to face in the post-pandemic world. An aspect that is strongly contributing to the ongoing crisis is the systematic lack of reliable information to guide healthcare professionals and policymakers. To apply a network approach to COVID-19 research, we should prioritize the “hubs” connecting the different domains of COVID-19 consequences. Mental health is surely one of the health domains that are being more strongly affected by COVID-19 outcomes. Isolation, psychological stress, and “free-time” boredom induced by COVID-19 restrictions have been consistently associated with increased internalizing symptoms, including anxiety and depression. Additionally, traumatic experiences related to COVID-19 (e.g., severe symptoms, hospitalization, and death of a loved one) have been also linked to posttraumatic stress disorder. In a vicious circle, internalizing disorders have been associated with an increased risk of SARS-Cov-2 infection and COVID-19 severe symptoms, hospitalization, and mortality. For instance, SARS-Cov-2 infection and COVID-19 severity can be due to the effect of a weakened immune system associated with internalizing disorders. In recent years, genetic research has demonstrated to be an invaluable tool to dissect the underlying dynamics related to internalizing disorders and traits. Indeed, genetic information can be used as an anchor for causal inference to test the relationships linking human traits and diseases and to investigate the effect of genomic regulatory mechanisms on disease risk. Based on our expertise and the supporting findings generated by our studies, we propose a multivariate investigation to identify the latent factors linking the internalizing spectrum (anxiety, major depressive disorder, and posttraumatic stress disorder) and COVID-19 outcomes (infection, hospitalization, and critical illness). Then, we will investigate the regulatory mechanisms of these latent factors across multiple omics domains, tissues, and cell types. In parallel, we will also test the interaction of the internalizing spectrum with blood-based transcriptomic and epigenomic changes associated with COVID-19 morbidity and psychological stress. Our findings will provide a multi-dimensional perspective on the processes underlying the associations between COVID-19 outcomes and internalizing disorders.", "keywords": [ "2019-nCoV", "Address", "Affect", "Anxiety", "Biological", "Biological Process", "Biology", "Blood", "Blood specimen", "Boredom", "COVID-19", "COVID-19 impact", "COVID-19 morbidity", "COVID-19 pandemic", "COVID-19 risk", "COVID-19 severity", "COVID-19 susceptibility", "Cessation of life", "Complex", "Critical Illness", "Data", "Data Set", "Disease", "Economics", "Epidemiology", "Epigenetic Process", "Etiology", "Face", "Family member", "Fright", "Genetic", "Genetic Research", "Genomics", "Health", "Health Professional", "Herd Immunity", "Hospitalization", "Human", "Immune system", "Immunization Programs", "Individual", "Infection", "Infectious Agent", "Investigation", "Life", "Link", "Major Depressive Disorder", "Maps", "Medical", "Mental Depression", "Mental Health", "Mental disorders", "Molecular", "Molecular Target", "Outcome", "Participant", "Pathway interactions", "Post-Traumatic Stress Disorders", "Process", "Proteomics", "Psychological Stress", "Recording of previous events", "Recovery", "Reporting", "Research", "Research Personnel", "Risk", "SARS-CoV-2 infection", "Social isolation", "Societies", "Socioeconomic Status", "Source", "Symptoms", "Testing", "Time", "Tissues", "Trauma", "Uncertainty", "Underrepresented Minority", "Vaccines", "Veterans", "base", "biobank", "body system", "cell type", "cohort", "comorbidity", "contagion", "disorder risk", "epigenome", "epigenomics", "experience", "genetic information", "genome wide association study", "genome-wide", "genome-wide analysis", "genomic data", "health disparity", "high risk", "improved", "infection risk", "loved ones", "mortality", "multiple omics", "pandemic disease", "phenome", "physical conditioning", "pleiotropism", "programs", "psychiatric comorbidity", "public health relevance", "recruit", "respiratory", "severe COVID-19", "social", "therapy design", "tool", "trait", "transcriptome", "transcriptomics" ], "approved": true } }, { "type": "Grant", "id": "10377", "attributes": { "award_id": "75N93022C00046-0-9999-1", "title": "SBIR TOPIC 107 AFFINITY REAGENTS FOR THE IMMUNE SYSTEM OF GOLDEN HAMSTER", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2024-09-29", "award_amount": 600000, "principal_investigator": { "id": 26355, "first_name": "HONG", "last_name": "QI", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1926, "ror": "", "name": "QOOLABS, INC.", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Syrian golden hamsters are valuable animal models for studying metabolic disease and human infectious diseases including SARS-CoV-2. However, the usefulness of the hamster as a small animal model for biomedical research has been constrained by the lack of immunological reagents. In this proposal, the Offeror proposes to develop affinity reagents for eight immune targets of Syrian golden hamsters that are relevant to SARS-CoV-2 infections and host immune responses, and to evaluate affinity and specificity of the produced antibodies using recombinant proteins and endogenous targets expressed by immune cells from hamsters. Successful completion of the proposed work will result in a comprehensive portfolio of antibodies that facilitate pre-clinical studies on SARS-CoV-2.", "keywords": [ "2019-nCoV", "Affinity", "Animal Model", "Antibodies", "Antigens", "Binding", "Biomedical Research", "Cells", "Communicable Diseases", "Hamsters", "Human", "Immune", "Immune Targeting", "Immune response", "Immune system", "Immunologic Markers", "Immunologics", "Mesocricetus auratus", "Metabolic Diseases", "Monoclonal Antibodies", "Oryctolagus cuniculus", "Production", "Reagent", "Recombinant Proteins", "SARS-CoV-2 infection", "Small Business Innovation Research Grant", "Specificity", "Technology", "Work", "metabolic abnormality assessment", "preclinical study" ], "approved": true } }, { "type": "Grant", "id": "10379", "attributes": { "award_id": "75N93022C00044-0-9999-1", "title": "SBIR TOPIC 107 REAGENTS FOR IMMUNOLOGIC ANALYSIS OF NON- MAMMALIAN AND UNDERREPRESENTED MAMMALIAN MODELS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2024-09-29", "award_amount": 596519, "principal_investigator": { "id": 24917, "first_name": "TORI", "last_name": "RACE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "The hamster is a well-established model for several infectious diseases including influenza and SARS-CoV-2. Lack of hamster reagents has hampered pre-clinical studies of viral pathogenesis, host immunity, and vaccine development. The objectives of this proposal are to produce and test monoclonal antibodies against 10 cytokines and chemokines and 4 T cell surface markers for characterizing cytokine responses and examining T cells activation in the hamster models of respiratory infections. Completion of this project will provide high-affinity monoclonal antibodies that allow investigators to distinguish innate and adaptive inflammatory cytokine and chemokine responses as well as activated T cells, memory T cells, tissue resident memory T cells, and regulatory T cells in the hamster models of infectious diseases.", "keywords": [ "2019-nCoV", "Affinity", "Cell surface", "Cells", "Communicable Diseases", "Generations", "Hamsters", "Immunity", "Immunization", "Immunologics", "Inflammatory", "Influenza", "Memory", "Modeling", "Monoclonal Antibodies", "Mus", "Proteins", "Reagent", "Recombinant Proteins", "Recombinants", "Regulatory T-Lymphocyte", "Research Personnel", "Respiratory Tract Infections", "Serum", "Small Business Innovation Research Grant", "T memory cell", "T-Cell Activation", "T-Lymphocyte", "Testing", "Tissue Sample", "Tissues", "Validation", "Viral Pathogenesis", "chemokine", "cytokine", "infectious disease model", "preclinical study", "response", "vaccine development" ], "approved": true } }, { "type": "Grant", "id": "10380", "attributes": { "award_id": "1R03OH012395-01", "title": "Longitudinal Trajectories of Workplace Violence and Worker Health Among Child Protective Services Workers", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24557, "first_name": "Sharon", "last_name": "Chiou", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2024-08-31", "award_amount": 77000, "principal_investigator": { "id": 26358, "first_name": "Melissa", "last_name": "Radey", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 343, "ror": "https://ror.org/05g3dte14", "name": "Florida State University", "address": "", "city": "", "state": "FL", "zip": "", "country": "United States", "approved": true }, "abstract": "Workplace violence, or the act or threat of verbal abuse or physical violence directed toward workers completing their jobs, is rampant and harmful to workers in the health and social assistance sector. Estimates suggest that 62% to 97% of these workers experience violence in their careers. Moreover, violence in the sector has risen over the last decade, and, an apparent surge during the Coronavirus pandemic poses an “international emergency” undermining health systems. The human and economic tolls of workplace violence are high including physical injury, psychological illness, lost productivity, and lower service quality. Workers in this sector have a non-fatal workplace injury rate 5 times that of all U.S. workers (10.4 vs. 2.1 per 10,000 workers) and account for 73% of U.S. workplace injuries. One group in this sector, Child Protective Services (CPS) workers, responsible for investigating and providing services to families with alleged or verified child abuse or neglect, are particularly vulnerable to violence, specifically client violence in which the perpetrator becomes violent while receiving client services. The nature of CPS work (e.g., threat of child removal, hostile clients, dangerous neighborhoods) places workers in unique and violent-prone environments. The overall goal of this project is to examine the longitudinal prevalence and health consequences of client violence among CPS workers. Specifically, this study aims to (1) determine the 3-year longitudinal trajectories of client violence by subtype (i.e., verbal abuse, threat, physical); (2) test the role of client violence in predicting worker health over time; and (3) determine the extent to which client violence trajectories and job demands and supports interact to influence workers’ health trajectories. We will use data from the Florida Study of Professionals for Safe Families (FSPSF), a statewide, longitudinal cohort study of CPS workers (N = 1,500) that we collected to provide insight into CPS work and worker wellbeing. This project is significant because it responds to NIOSH’s (2019) Strategic Goal 1 by tracking work-related injuries and illnesses and generating knowledge to inform intervention strategies. Moreover, analyzing worker attributes; job demands and supports; violence type and accumulation; and health consequences addresses NORA’s (2019) Research Agenda Objective 3 by examining the epidemiology of workplace violence and identifying strategies for prevention and mitigation. The project offers conceptual innovation by examining client violence and worker health longitudinally among a cohort of CPS workers over the first three years on the job, the time of highest turnover and increased risk of violence. Our use of advanced statistical longitudinal modeling to provide stronger evidence of explanatory pathways not determined in current research is methodologically innovative. The frequency and intensity of client violence among the health and social assistance sector and its potential role in worker health amplify the need to examine violence, its accumulation over worker tenure, and the consequences for worker health.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10381", "attributes": { "award_id": "1R43OH012358-01", "title": "Anti-viral Active Air-Purifying Respirator with Photocatalytic Microreactor to Prevent Airborne Diseases", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 25093, "first_name": "Marcienne", "last_name": "Wright", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2023-08-31", "award_amount": 243500, "principal_investigator": { "id": 26359, "first_name": "M Arifur ARIFUR", "last_name": "Rahman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1927, "ror": "", "name": "HAWAI'I INNOVATION LABORATORY, INC.", "address": "", "city": "", "state": "HI", "zip": "", "country": "United States", "approved": true }, "abstract": "The potential for an epidemic or pandemic caused by a high-impact respiratory pathogen is increasing. Studies prior to the COVID-19 outbreak show that the frequency of outbreaks of newly emerging diseases rose, which has exacerbated since the pandemic started. Respiratory protective masks are used whenever airborne contaminants such as dust, fumes, smoke, and mists are present in the air. The contaminants also include airborne bacteria, viruses, and fungi. Currently, most commercially available untethered protective masks are designed for surgical or industrial safety and may provide adequate protection from airborne contaminants but do so through particle filtering. Therefore, most masks do not kill the pathogens to protect the wearers. Hence, while using an active respirator, the filtered pathogens, which are alive and infectious, may enter the respiratory tract overtime or spread by touch. The current active respirators are bulky, heavy, and designed for 2-4 hours of use. In brief, the protective masks are not designed for prolonged daily use by untrained users. Until the outbreak of COVID-19, the necessity of an anti-pathogenic wearable respirator was not as significant as it is now. This COVID-19 has exposed our lack of preparedness in providing a safe working environment for the frontline workers during the respiratory pandemic. Most current protective respirators address only part of the desired solution. A working solution needs to combine all the critical requirements, such as high filtration (≥ 99%) for nanometer-scale particles, pathogens-neutralization, moisture dissipation, eco-friendliness, and comfortable prolonged use. The proposed R&D effort addresses a wearable anti-pathogenic respirator's critical need for prolonged use by trained or untrained users. We propose designing and developing an active, untethered, anti- pathogen full-face breathing mask with an integrated photocatalytic microreactor that can neutralize all microorganisms, including viruses SARS-CoV-2. Although the proposed system contains all the components of a portable respirator, the components are miniaturized and integrated into a full-face mask. Hence, the system is referred to as a full-face mask in this proposal. The proposed full-face mask intakes surrounding air filters out particles as small as 100 nm (size of a single SARS-CoV-2 viral particle), passes the air through an integrated photocatalytic microreactor killing all the microorganisms, and volatile organic chemicals (VOCs), and supply clean air to the user. The mask also works as a defense against the threat of contamination of ventilation systems by bioterrorism. The mask is completely untethered and designed to run for 8-10 hours with a single charge. The active-powered mask can save the wearer from airborne pathogens while maintaining visibility and comfort.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10382", "attributes": { "award_id": "1U18FD007730-01", "title": "COVID-19: Enhancing testing and sequencing capacity for Severe Acute Respiratory Syndrome Coronavirus 2 and other zoonotic viruses at the Minnesota Veterinary Diagnostic Laboratory", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 26272, "first_name": "Megan", "last_name": "Miller", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2023-08-31", "award_amount": 89694, "principal_investigator": { "id": 26360, "first_name": "Albert", "last_name": "Rovira", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 764, "ror": "https://ror.org/017zqws13", "name": "University of Minnesota", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true }, "abstract": "Enhancing testing and sequencing capacity for Severe Acute Respiratory Syndrome Coronavirus 2 and other zoonotic viruses at the Minnesota Veterinary Diagnostic Laboratory The Minnesota Veterinary Diagnostic Laboratory (MVDL) has the capability of testing for SARS-CoV-2 by PCR. The MVDL was critical during the first phase of the response to the pandemic by testing human samples while the state of Minnesota acquired the capacity to respond to the testing needs. The MVDL is the reference laboratory for SARS-CoV-2 testing in animal samples in Minnesota. This proposal requests funding for equipment to improve laboratory capacity to test for SARS-CoV-2 by PCR and to sequence positive samples. These improvements would also benefit the capacity to respond to other zoonotic diseases. The SARS-CoV-2 PCR test is currently performed in an Applied Biosystems 7500 thermal cycler, which can test 93 samples at a time. To improve the efficiency of the process, we propose to purchase a Quantstudio 6 Pro thermal cycler, which can process 378 samples at a time. Sequencing of SARS-Co-2-positive samples is an important component of disease surveillance. Sequencing allows for identification of new variants and monitoring of variants of concern. The MVDL performs routine sequencing for multiple viral pathogens, and could easily start sequencing SARS-CoV-2 if needed. The MVDL has expertise sequencing viruses from a wide variety of specimens, some with low amounts of DNA/RNA. The initial PCR amplification step performed as part of the sequencing process is currently done with ABI 9700 GenAmp PCR instruments, which are old and do not have maintenance and repair parts available anymore. Therefore, we propose to purchase a Proflex 96-well thermal cycler from Life Technologies/Thermo Fisher. The addition of this instrument will add sequencing capacity to the lab so SARS-CoV-2 sequencing can be performed in addition to the routine sequencing procedures currently being run.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1383, "pages": 1424, "count": 14236 } } }